Lilly's psoriatic arthritis drug succeeds in late-stage study

April 20, 2015 12:45 PM

1 0

(Reuters) - Eli Lilly and Co said its experimental drug, ixekizumab, reduced the signs and symptoms of active psoriatic arthritis in patients more than a placebo did in a late-stage trial.

Up to 30 percent of psoriasis patients develop psoriatic arthritis, an inflammatory form of arthritis that can cause swelling, stiffness and pain in and around joints, according to the National Psoriasis Foundation.

Also read: China Growth Holds at 6.7%, Backed by Government and Consumers

Read more

To category page